Exelixis, Inc. (NASDAQ:EXEL) has earned an average recommendation of “Buy” from the fifteen analysts that are covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $31.71.

A number of research firms have issued reports on EXEL. TheStreet raised Exelixis from a “c” rating to a “b-” rating in a research report on Monday, August 7th. Cowen reissued an “outperform” rating on shares of Exelixis in a research report on Thursday, August 10th. Needham & Company LLC raised their target price on Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Oppenheimer reissued a “hold” rating on shares of Exelixis in a research report on Monday, September 25th. Finally, BidaskClub downgraded Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 14th.

In related news, Director Stelios Papadopoulos sold 10,000 shares of the business’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $25.40, for a total transaction of $254,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Christopher J. Senner sold 100,000 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $26.79, for a total value of $2,679,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 970,152 shares of company stock valued at $25,923,457. 5.10% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of EXEL. Mark Sheptoff Financial Planning LLC purchased a new position in Exelixis during the third quarter worth about $120,000. Fisher Asset Management LLC purchased a new position in Exelixis during the third quarter worth about $213,000. Wetherby Asset Management Inc. purchased a new position in Exelixis during the second quarter worth about $218,000. Caxton Associates LP purchased a new position in Exelixis during the second quarter worth about $227,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in Exelixis during the third quarter worth about $236,000. Institutional investors and hedge funds own 81.19% of the company’s stock.

Shares of Exelixis (EXEL) opened at $28.12 on Monday. The company has a market capitalization of $8,319.39, a price-to-earnings ratio of 55.14, a P/E/G ratio of 1.26 and a beta of 1.89. Exelixis has a fifty-two week low of $14.22 and a fifty-two week high of $32.50.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, topping the Zacks’ consensus estimate of $0.08 by $0.18. The business had revenue of $152.50 million for the quarter, compared to analyst estimates of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. Exelixis’s quarterly revenue was up 145.2% compared to the same quarter last year. During the same period last year, the company posted ($0.04) earnings per share. equities analysts expect that Exelixis will post 0.49 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/04/exelixis-inc-exel-given-consensus-rating-of-buy-by-brokerages.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.